title: High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication.
abstract: OBJECTIVE
  To compare high-dose versus low-dose clarithromycin in 1-week triple therapy including rabeprazole and levofloxacin.
  
  
  BACKGROUND
  Regimens containing rabeprazole and levofloxacin have proved to be effective against H. pylori infection.
  
  
  METHODS
  One-hundred H. pylori-positive patients were randomly assigned to one of the following 1-week regimens: rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and clarithromycin 250 mg b.d. (RLC-1 group); rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and clarithromycin 500 mg b.d. (RLC-2 group). H. pylori status was assessed at entry and after the treatment. Patients who experienced treatment failure underwent antibiotic susceptibility testing.
  
  
  RESULTS
  Forty-two patients in RLC-1 group (both PP and ITT analysis: 84%; 95%CI: 71-93%) and 47 in RLC2 group (both PP and ITT analysis: 94%; 95% CI: 83-98%) became H. pylori negative. Clarithromycin resistance was detected in all of 8 (100%) RLC-1 failures and in 1 out of 3 (33%) RLC-2 failures. Side effects occurred in 8% of patients in RLC-1 group and in 12% in RLC-2.
  
  
  CONCLUSIONS
  Regimens tested are competitive with other PPI-based treatments. One-week triple therapy containing rabeprazole plus, levofloxacin, and high-dose clarithromycin yielded a higher eradicating rate than the one containing low-dose clarithromycin and may be considered as a first-line therapy option.
authors.affiliation: Department of Internal Medicine, Institute of Microbiology, Catholic University of Rome, Italy. gcammarota@rm.unicatt.it
authors.forename: Giovanni
authors.initials: G
authors.lastname: Cammarota
authors.forename: Rossella
authors.initials: R
authors.lastname: Cianci
authors.forename: Oreste
authors.initials: O
authors.lastname: Cannizzaro
authors.forename: Antonio
authors.initials: A
authors.lastname: Martino
authors.forename: Paolo
authors.initials: P
authors.lastname: Fedeli
authors.forename: Piera Giuseppina
authors.initials: PG
authors.lastname: Lecca
authors.forename: Simona
authors.initials: S
authors.lastname: di Caro
authors.forename: Paola
authors.initials: P
authors.lastname: Cesaro
authors.forename: Giovanna
authors.initials: G
authors.lastname: Branca
authors.forename: Giovanni
authors.initials: G
authors.lastname: Gasbarrini
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001944:Breath Tests; D017291:Clarithromycin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use*; D009853:Omeprazole / Q000031:analogs & derivatives; D064750:Rabeprazole; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D064704:Levofloxacin; D015242:Ofloxacin; D017291:Clarithromycin; D009853:Omeprazole